SCHEMBL19505263

SCHEMBL19505263

CC(C)OCCOc1nc2c(c(=O)n(CCCOPI)c(=O)n2C)n1Cc1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ TRPC4 Q9UBN4 2/20 0.50
▸ TRPC5 Q9UL62 2/20 0.50
▸ KCNH2 Q12809 1/20 0.50
▸ MAPK1 P28482 2/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ TRPC1 P48995 1/20 0.46
▸ HIF1A Q16665 1/20 0.45
▸ KMT2A Q03164 2/20 0.44
▸ MAPT P10636 5/20 0.44
▸ TSHR P16473 3/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.44
▸ MAOA P21397 2/20 0.43
▸ MAOB P27338 2/20 0.43
▸ ATM Q13315 1/20 0.42
▸ LMNA P02545 2/20 0.42
▸ HTT P42858 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16076246 0.89 SMN1; SMN2 (0.54) SMN1; SMN2TRPC4TRPC5KCNH2MAPK1
SCHEMBL21499673 0.88 SMN1; SMN2 (0.54) SMN1; SMN2TRPC4TRPC5KCNH2MAPK1
SCHEMBL16076048 0.88 TRPC5 (0.64) SMN1; SMN2TRPC4TRPC5KCNH2MAPK1
SCHEMBL19505266 0.85 TRPC4 (0.47) SMN1; SMN2TRPC4TRPC5KCNH2MAPK1
SCHEMBL19505554 0.82 TRPC5 (0.68) SMN1; SMN2TRPC4TRPC5KCNH2MAPK1
SCHEMBL19505419 0.82 TRPC4 (0.49) SMN1; SMN2TRPC4TRPC5KCNH2MAPK1
SCHEMBL19505592 0.82 TRPC4 (0.49) SMN1; SMN2TRPC4TRPC5KCNH2MAPK1
SCHEMBL21316313 0.82 TRPC4 (0.47) SMN1; SMN2TRPC4TRPC5KCNH2MAPK1
SCHEMBL19505600 0.82 TRPC4 (0.47) SMN1; SMN2TRPC4TRPC5KCNH2MAPK1
SCHEMBL21499679 0.82 ALDH1A1 (0.68) SMN1; SMN2TRPC4TRPC5KCNH2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230040259-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, LLC (US) 2023-02-09 — — US disclosed
US-11208409-B2 Substituted xanthines and methods of use thereof HYDRA BIOSCIENCES, LLC (US) 2021-12-28 — — US disclosed
US-20190322667-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-10-24 — — US disclosed
US-10399982-B2 Substituted xanthines and methods of use thereof HYDRA BIOSCIENCES, INC. (US) 2019-09-03 — — US disclosed
US-9969736-B2 Substituted xanthines and methods of use thereof HYDRA BIOSCIENCES, INC. (US) 2018-05-15 — — US disclosed
US-20170305910-A1 Substituted Xanthines and Methods of Use Thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-10-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230040259-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 SMN1; SMN2 1307/4885TRPC4 3/4885TRPC5 1/4885
US-20170305910-A1 Substituted Xanthines and Methods of Use Thereof TRPC5, TRPC7, TRPC4 SMN1; SMN2 1307/4885TRPC4 3/4885TRPC5 1/4885
US-10399982-B2 Substituted xanthines and methods of use thereof TRPC5, TRPC7, TRPC4 SMN1; SMN2 1307/4885TRPC4 3/4885TRPC5 1/4885
US-11208409-B2 Substituted xanthines and methods of use thereof TRPC5, TRPC7, TRPC4 SMN1; SMN2 1307/4885TRPC4 3/4885TRPC5 1/4885
US-20190322667-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 SMN1; SMN2 1307/4885TRPC4 3/4885TRPC5 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback